Advertisement

Related Videos

David A. Hyman, MD, JD, on Inclusive Shared Savings

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Advertisement

Advertisement




Sep
14
Today In Oncology
FDA Approves Topical Photodynamic Therapy for Superficial BCC
Perioperative Atezolizumab Plus Chemotherapy Improves Outcomes in Resectable Stage II–IIIB NSCLC
New NCCN Survey Highlights Persistent Cancer Medication Shortages Across United States
What Constitutes Clinical Expertise in an AI-Enabled Era
NSCLC FDA Grants Accelerated Approval to Sevabertinib for Locally Advanced or Metastatic Nonsquamous Disease
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo